ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,580,000 | -12.7% | 39,700 | -7.7% | 0.21% | -34.1% |
| Q2 2021 | $4,100,000 | -45.4% | 43,000 | -34.8% | 0.32% | -50.5% |
| Q1 2021 | $7,515,000 | -39.0% | 66,000 | -25.8% | 0.65% | -32.4% |
| Q4 2020 | $12,319,000 | +90.7% | 89,000 | +13.2% | 0.96% | +82.4% |
| Q3 2020 | $6,460,000 | +4.5% | 78,600 | -0.5% | 0.53% | -33.8% |
| Q2 2020 | $6,180,000 | +261.2% | 79,000 | +105.2% | 0.80% | +143.6% |
| Q1 2020 | $1,711,000 | +640.7% | 38,500 | +612.7% | 0.33% | +628.9% |
| Q4 2019 | $231,000 | -87.0% | 5,402 | -80.7% | 0.04% | -87.1% |
| Q2 2019 | $1,778,000 | +66.9% | 28,000 | +169.2% | 0.35% | -27.3% |
| Q2 2015 | $1,065,000 | – | 10,400 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |